Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancerGiampaolo Bianchini, Luca Gianni|Breast Cancer Research|2017Cited by 129
First-Line Camizestrant for Emerging <i>ESR1</i> -Mutated Advanced Breast CancerFrançois‐Clément Bidard, Nicholas C. Turner, Erica L. Mayer et al.|New England Journal of Medicine|2025Cited by 106
Design of SERENA-6, a phase III switching trial of camizestrant in <i>ESR1</i> -mutant breast cancer during first-line treatmentNicholas C. Turner, François‐Clément Bidard, Stephen Chia et al.|Future Oncology|2023Cited by 78
Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.Kevin Kalinsky, Seth A. Wander, Giampaolo Bianchini et al.|Journal of Clinical Oncology|2024Cited by 75
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?Chiara Corti, Carmen Criscitiello, Carmine De Angelis et al.|Cancer Treatment Reviews|2023Cited by 54